|
UNITED STATES |
|
|
SECURITIES AND EXCHANGE COMMISSION |
|
|
Washington,
D.C. 20549 |
|
|
SCHEDULE 13G |
|
Under
the Securities Exchange Act of 1934
(Amendment No. )*
SANGAMO BIOSCIENCES, INC.
(Name of Issuer)
Common Stock, $.01 par value per share
(Title of Class of Securities)
800677106
(CUSIP Number)
December 22, 2006
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o |
Rule 13d-1(b) |
x |
Rule 13d-1(c) |
o |
Rule 13d-1(d) |
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. |
|
|||||
|
|
|||||
|
1. |
Names of Reporting
Persons. I.R.S. Identification Nos. of above persons (entities only) 33-4316614 |
|
|||
|
|
|||||
|
2. |
Check the Appropriate Box if a Member of a Group (See Instructions) |
|
|||
|
|
(a) |
o |
|
||
|
|
(b) |
o |
|
||
|
|
|||||
|
3. |
SEC Use Only |
|
|||
|
|
|||||
|
4. |
Citizenship or Place of
Organization |
|
|||
|
|
|
||||
Number of |
5. |
Sole Voting Power |
||||
|
||||||
6. |
Shared Voting Power
|
|||||
|
||||||
7. |
Sole Dispositive Power
|
|||||
|
||||||
8. |
Shared Dispositive Power |
|||||
|
|
|||||
|
9. |
Aggregate Amount
Beneficially Owned by Each Reporting Person |
|
|||
|
|
|||||
|
10. |
Check if the Aggregate
Amount in Row (9) Excludes Certain Shares (See Instructions) o |
|
|||
|
|
|||||
|
11. |
Percent of Class
Represented by Amount in Row (9) |
|
|||
|
|
|||||
|
12. |
Type of Reporting Person
(See Instructions) |
|
|||
2
Item 1. |
|||
|
(a) |
Name of Issuer |
|
|
(b) |
Address of Issuers
Principal Executive Offices |
|
|
|||
Item 2. |
|||
|
(a) |
Name of Person Filing |
|
|
(b) |
Address of Principal
Business Office or, if none, Residence |
|
|
(c) |
Citizenship |
|
|
(d) |
Title of Class of
Securities |
|
|
(e) |
CUSIP Number |
|
|
|||
Item 3. |
If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
||
|
(a) |
o |
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). |
|
(b) |
o |
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). |
|
(c) |
o |
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). |
|
(d) |
o |
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). |
|
(e) |
o |
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); |
|
(f) |
o |
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); |
|
(g) |
o |
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); |
|
(h) |
o |
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); |
|
(i) |
o |
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); |
|
(j) |
o |
Group, in accordance with §240.13d-1(b)(1)(ii)(J). |
|
|
|
This Item 3 is not applicable. |
3
Item 4. |
Ownership |
||
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. |
|||
|
(a) |
Amount beneficially owned: As of the date hereof, Edwards Lifesciences Corporation is the beneficial owner of 1,842,454 Shares. |
|
|
(b) |
Percent of class: The number of Shares beneficially owned by Edwards Lifesciences Corporation constitutes approximately 5.26% of the total number of Shares outstanding as of February 1, 2007 (based upon information provided by the Issuer in its most recently-filed quarterly report on Form 10-K, there were 35,049,862 Shares outstanding as of February 1, 2007). |
|
|
(c) |
Number of shares as to which the person has: |
|
|
|
|
Edwards Lifesciences Corporation: |
|
|
(i) |
Sole power to vote or to direct the vote 1,842,454 |
|
|
(ii) |
Shared power to vote or to direct the vote 0 |
|
|
(iii) |
Sole power to dispose or to direct the disposition of 1,842,454 |
|
|
(iv) |
Shared power to dispose or to direct the disposition of 0 |
|
|||
Item 5. |
Ownership of Five Percent or Less of a Class |
||
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o. |
|||
|
This Item 5 is not applicable. |
||
|
|
||
Item 6. |
Ownership of More than Five Percent on Behalf of Another Person |
||
|
This Item 6 is not applicable. |
||
|
|||
Item 7. |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company |
||
|
See disclosure in Item 2 hereof. |
||
|
|||
Item 8. |
Identification and Classification of Members of the Group |
||
|
This Item 8 is not applicable. |
||
|
|||
Item 9. |
Notice of Dissolution of Group |
||
|
This Item 9 is not applicable. |
||
|
|||
Item 10. |
Certification |
||
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. |
4
Date: April 2, 2007 |
EDWARDS LIFESCIENCES CORPORATION |
|||
|
|
|||
|
|
|
||
|
By: |
/s/ Jay P. Wertheim |
|
|
|
Name: |
Jay P. Wertheim |
||
|
Title: |
Vice President, Associate General Counsel |
||
5